GenScript Trastuzumab Pharmacokinetic ELISA Kit

GenScript Trastuzumab, also known as Herceptin, is a human epidermal growth factor receptor 2 (HER2) inhibitor for the treatment of breast cancer. Trastuzumab is a recombinant humanized IgG1 kappa monoclonal antibody. It binds to the extracellular domain of the HER2 protein on the on the surface of HER2-positive tumour cells with high affinity. Trastuzumab can suppress the cells growth and proliferation by blocking the ability of the cancer cells to receive chemical signals.
GenScript’s Trastuzumab Pharmacokinetic ELISA Kit had been comprehensively developed and validated for quantitative measurement of Trastuzumab in cynomolgus monkeyserum and plasma, based on the ICH M10 and the FDA bioanalytical method validation guidance for industry. Its precision, accuracy, dilutional linearity, specificity, selectivity, stability, and hook effect were acceptable according to the guidances^[1-4]. The Trastuzumab ELISA kit is a validated tool for whole Trastuzumab and its biosimilar quantification in biological matricesfor drug research and development. - GSCRPT (Additional S&H or Hazmat Fees May Apply)